Order Center
 
Product Catalog →  Cancer Research →  Antitumor Agents →  Therapy Adjuncts
 Print Preview

Therapy Adjuncts

Image
Description
Biochem/physiol Actions
CAS Number
Product #
(−)-Scopolamine hydrobromide trihydrate ≥98% (TLC), powder Competitive nonselective muscarinic acetylcholine antagonist. Scopolamine-induced amnesia in laboratory animals is a commonly-used model of memory deficit.
114-49-8 S1875
4-Amino-1,8-naphthalimide Sensitizes cells to radiation-induced cell damage and enhances the cytotoxicity of 1-methyl-3-nitro-1-nitrosoguanidine.
1742-95-6 A0966
Amifostine ≥97% (TLC), powder Radioprotective agent. Selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy. Selectivity is due to preferential uptake by normal tissues and subsequent metabolic activation to 2-(3-aminopropyl)aminoethanethiol.
20537-88-6 A5922
Brefeldin A from Penicillium brefeldianum, ≥99% (HPLC and TLC) Brefeldin A (BFA) is a fungal metabolite which disrupts the structure and function of the Golgi apparatus. BFA is an activator of the sphingomyelin cycle. Brefeldin A-mediated apoptosis has been observed in human tumor cells.
20350-15-6 B7651
Cimetidine H2 histamine receptor antagonist; I1 imidazoline receptor agonist; anti-ulcer agent. Blocks cancer metastasis by inhibiting the expression of E-selectin on the surface of endothelial cells, thus blocking tumor cell adhesion.
51481-61-9 C4522
Lectin from Viscum album (European mistletoe) lyophilized powder VAA is not blood group specific, but has an affinity for terminal β-D-galactosyl residues.1 VAA inhibits protein synthesis similarly to Ricin (RCA60) and inhibits allergen induced histamine release in vitro from human leukocytes.2
L2662
Leuprolide acetate salt ≥98% (HPLC) Luteinizing hormone releasing hormone (LH-RH) agonist.
74381-53-6 L0399
Luteinizing hormone releasing hormone human acetate salt ≥98% (HPLC), powder Hypothalamic peptide that stimulates release of gonadotrophins from anterior pituitary, thus regulating reproductive functions.
71447-49-9 L7134
Papaverine hydrochloride powder Smooth muscle relaxant and cerebral vasodilator; phosphodiesterase inhibitor.
61-25-6 P3510
Phosphomycin disodium salt Antibiotic that concentrates in kidney and bladder; reduces nephrotoxicity and ototoxicity of platinum-containing anti-tumor agents. Fosfomycin inhibits UDP-GlcNAc enolpyruvyl tranferase (MurA), an enzyme involved in bacterial cell wall biosynthesis.
26016-99-9 P5396
Pifithrin-α ≥95% (HPLC), powder Pifithrin-α is a reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription such as cyclin G, p21/waf1, and mdm2 expression. Pifithrin-α enhances cell survival after genotoxic stress such as UV irradiation and treatment with cytotoxic compounds including doxorubicin, etopoxide, paclitaxel, and cytosine-β-D-arabinofuranoside. Pifithrin-α protects mice from lethal whole body γ-irradiation without an increase in cancer incidence. The protective effect is not seen in p53-null mice or cells expressing a dominant negative mutant of the p53 gene. Protection is conferred by the transient expression of p53 in p53-deficient cell lines.
63208-82-2 P4359
Thapsigargin ≥90% (HPLC), liquid or film Potent, cell-permeable, IP3-independent intracellular calcium releaser. Blocks the transient increase in intracellular Ca2+ induced by angiostatin and endostatin. Induces apoptosis by disrupting intracellular free Ca2+ levels; incorporated into chemotherapeutic prodrug formulations.
67526-95-8 T9033
[D-Lys6]-LH-RH ≥95% (HPLC), powder LH-RH agonist. It has been conjugated to cytotoxic compounds such as methotrexate (MTX), doxorubicin (DOX), and glutaryl-2-(hydroxymethyl)anthraquinone (G-HMAQ), and together with other conjugated LH-RH analogs comprise a class of targeted chemotherapeutic agents for cancers expressing receptors for LH-RH.
52671-12-2 L5022
[D-Trp6]-LH-RH ≥97% (HPLC), powder Potent LH-RH agonist with enhanced biological activity due to its slower rate of degradation. Like [D-Lys6]-LH-RH, the D-Trp6 analog has been shown to be effective against cancers expressing the LH-RH receptor. However, unlike the D-Lys6 analog, it is generally used in the unconjugated form.
57773-63-4 L9761

 Site Use Terms Terms and Conditions of Sale Privacy
Copyrights © 2008 Sigma-Aldrich Co. All Rights Reserved. Reproduction of any materials from the site is strictly forbidden without permission. Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich, Inc.